Ocumension Therapeutics
5DG
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
489
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.70 | 48.80 | 0.56% |
| CAC 40 | 7,902.25 | 23.79 | 0.30% |
| DAX 40 | 24,456.81 | 92.75 | -0.38% |
| Dow JONES (US) | 44,676.74 | 218.44 | 0.49% |
| FTSE 100 | 8,975.66 | 108.64 | 1.23% |
| HKSE | 24,028.37 | 136.05 | 0.57% |
| NASDAQ | 20,600.92 | 10.42 | -0.05% |
| Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
| NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
| S&P 500 | 6,275.25 | 11.99 | 0.19% |
| S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
| SSE Composite Index | 3,509.68 | 16.63 | 0.48% |